Current Targets for Primary Sclerosing Cholangitis

Curr Drug Targets. 2017;18(8):901-907. doi: 10.2174/1389450117666160112114152.

Abstract

Primary sclerosing cholangitis (PSC) is a biliary disease characterized by liver inflammation and death of cholangiocytes which, in turn, drive to fibrosis, cirrhosis and functional alterations of the liver. PSC is also associated with an increased risk of developing cholangiocarcinoma. To date, the etiopathogenesis of PSC is still not completely understood, although a genetic predisposition in association to environmental factors contribute to immune-mediated liver damage. The lack of such knowledge is responsible for the failure of most available therapies. At this time, many studies are evaluating potential approaches that could have a positive impact on the progression of the disease. This review aims to provide a summary of present and past therapeutic approaches for PSC.

Keywords: Primary sclerosing cholangitis; cholestasis; diagnosis; inflammatory bowel disease; pathogenesis; treatment.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bile Acids and Salts / metabolism
  • Cholangitis, Sclerosing / metabolism*
  • Cholangitis, Sclerosing / therapy
  • Digestive System Surgical Procedures
  • Disease Progression
  • Gene Regulatory Networks*
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use
  • Microbiota* / drug effects
  • Molecular Targeted Therapy
  • Receptors, Cytoplasmic and Nuclear / drug effects
  • Receptors, Cytoplasmic and Nuclear / metabolism

Substances

  • Anti-Bacterial Agents
  • Bile Acids and Salts
  • Immunosuppressive Agents
  • Receptors, Cytoplasmic and Nuclear